v3.25.2
Revenue Recognition - Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
 [1]
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue $ 983,518 $ 793,329 $ 2,347,859 $ 1,610,363  
Cost of revenue 397,686 266,445 818,133 514,488  
Gross profit 585,832 526,884 $ 1,529,726 1,095,875  
Gross Profit %     65.15%    
Net loss (1,305,785) $ (2,076,620) $ (2,065,825) $ (4,037,640)  
Assets 4,486,828   4,486,828   $ 3,821,429
Global Stem Cells Group [Member]          
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue     2,347,859    
Cost of revenue     818,133    
Gross profit     $ 1,529,726    
Gross Profit %     65.15%    
Net loss     $ (7,579)    
Assets 2,666,976   2,666,976    
Regenerative Medical Technology Group [Member]          
Schedule of Revenues, Cost of Revenues, Gross Profits, Assets and Net Loss [Line Items]          
Revenue        
Cost of revenue        
Gross profit        
Gross Profit %     0.00%    
Net loss     $ (2,058,246)    
Assets $ 1,819,853   $ 1,819,853    
[1] Derived from audited information